239 related articles for article (PubMed ID: 38612819)
1. Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer.
Muniz IAF; Araujo M; Bouassaly J; Farshadi F; Atique M; Esfahani K; Bonan PRF; Hier M; Mascarella M; Mlynarek A; Alaoui-Jamali M; Silva SDD
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612819
[TBL] [Abstract][Full Text] [Related]
2. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
3. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma.
Fung N; Faraji F; Kang H; Fakhry C
Cancer Metastasis Rev; 2017 Sep; 36(3):449-461. PubMed ID: 28812214
[TBL] [Abstract][Full Text] [Related]
4. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
5. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar S; Marko S; Ivica L
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4599-4603. PubMed ID: 33599841
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival.
Lee HI; Lee J; Lee JH; Wu HG; Kim JH; Kim Y; Eom KY
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1059-1067. PubMed ID: 36173618
[TBL] [Abstract][Full Text] [Related]
7. A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The "ALARM" study.
Agelaki S; Boukovinas I; Athanasiadis I; Trimis G; Dimitriadis I; Poughias L; Morais E; Sabale U; Bencina G; Athanasopoulos C
Cancer Med; 2024 Feb; 13(3):e6916. PubMed ID: 38247106
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options.
Chau NG; Rabinowits G; Haddad RI
Curr Treat Options Oncol; 2014 Dec; 15(4):595-610. PubMed ID: 25240410
[TBL] [Abstract][Full Text] [Related]
9. Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?
Mirghani H; Lacroix L; Rossoni C; Sun R; Aupérin A; Casiraghi O; Villepelet A; Lacave R; Faucher G; Marty V; Ferté C; Soria JC; Even C
Eur J Cancer; 2018 May; 94():61-69. PubMed ID: 29533868
[TBL] [Abstract][Full Text] [Related]
10. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status.
Fullerton ZH; Butler SS; Mahal BA; Muralidhar V; Schoenfeld JD; Tishler RB; Margalit DN
Cancer; 2020 Apr; 126(7):1424-1433. PubMed ID: 31930488
[TBL] [Abstract][Full Text] [Related]
11. p16, HPV, and Cetuximab: What Is the Evidence?
Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB
Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
13. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management.
Maxwell JH; Grandis JR; Ferris RL
Annu Rev Med; 2016; 67():91-101. PubMed ID: 26332002
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.
Rischin D; King M; Kenny L; Porceddu S; Wratten C; Macann A; Jackson JE; Bressel M; Herschtal A; Fisher R; Fua T; Lin C; Liu C; Hughes BGM; McGrath M; McDowell L; Corry J
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):876-886. PubMed ID: 34098030
[TBL] [Abstract][Full Text] [Related]
16. Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions.
Price KAR; Nichols AC; Shen CJ; Rammal A; Lang P; Palma DA; Rosenberg AJ; Chera BS; Agrawal N
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-13. PubMed ID: 32213088
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer.
Dahlstrom KR; Anderson KS; Field MS; Chowell D; Ning J; Li N; Wei Q; Li G; Sturgis EM
Cancer; 2017 Dec; 123(24):4886-4894. PubMed ID: 28898394
[TBL] [Abstract][Full Text] [Related]
18. Oropharyngeal cancer - is it time to change management according to human papilloma virus status?
Mehanna H; Olaleye O; Licitra L
Curr Opin Otolaryngol Head Neck Surg; 2012 Apr; 20(2):120-4. PubMed ID: 22327790
[TBL] [Abstract][Full Text] [Related]
19. Current treatment options for metastatic head and neck cancer.
Price KA; Cohen EE
Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
[TBL] [Abstract][Full Text] [Related]
20. Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.
Hanna GJ; Kacew A; Chau NG; Shivdasani P; Lorch JH; Uppaluri R; Haddad RI; MacConaill LE
JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
